How would you approach a patient with metastatic squamous NSCLC that progressed on carbo/paclitaxel/pembro and has a FGFR3 S249C mutation?

It is unclear if erda will have efficacy here in nsclc. If no trial available can consider gem while working on potential off label if patient interested, though there is an ongoing study looking at this, which would be best option.